Albumin Administration in Critically Ill Patients
Audience: Critical care healthcare professionals
The FDA notified healthcare professionals of an update and revision to a 1998 notice with advice regarding the safety of albumin administration in critically ill patients. This action has been taken following FDA’s review of recent studies on the safety of albumin, and is consistent with recommendations made on March 17, 2005 by members of the Blood Products Advisory Committee (BPAC).
[May 16, 2005 - Notice - FDA]